Motonori Aoki

414 total citations
18 papers, 343 citations indexed

About

Motonori Aoki is a scholar working on Molecular Biology, Pharmacology and Pharmacology. According to data from OpenAlex, Motonori Aoki has authored 18 papers receiving a total of 343 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 5 papers in Pharmacology and 4 papers in Pharmacology. Recurrent topics in Motonori Aoki's work include Phosphodiesterase function and regulation (5 papers), Drug-Induced Hepatotoxicity and Protection (4 papers) and Electrolyte and hormonal disorders (3 papers). Motonori Aoki is often cited by papers focused on Phosphodiesterase function and regulation (5 papers), Drug-Induced Hepatotoxicity and Protection (4 papers) and Electrolyte and hormonal disorders (3 papers). Motonori Aoki collaborates with scholars based in Japan, Norway and United States. Motonori Aoki's co-authors include Toshimitsu Yamada, Miki Kobayashi, Takeyuki Yatsu, Hiroichi Nagai, Kazuhisa Takayama, Akihide Koda, Kazuo Honda, Masao Kasahara, Masaya Orita and Hiroyuki Kurihara and has published in prestigious journals such as Journal of Medicinal Chemistry, Journal of Pharmacology and Experimental Therapeutics and European Journal of Pharmacology.

In The Last Decade

Motonori Aoki

18 papers receiving 322 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Motonori Aoki Japan 11 152 94 72 63 59 18 343
Kazuaki Naito United States 11 168 1.1× 52 0.6× 49 0.7× 102 1.6× 26 0.4× 32 347
Hiromi Sugimoto Japan 12 185 1.2× 56 0.6× 65 0.9× 186 3.0× 130 2.2× 23 525
Katsuo Ikezawa Japan 15 249 1.6× 120 1.3× 72 1.0× 227 3.6× 61 1.0× 47 585
Richard G. Conway United States 11 223 1.5× 71 0.8× 74 1.0× 113 1.8× 24 0.4× 24 458
Roberto P. Rosenkranz United States 12 188 1.2× 46 0.5× 70 1.0× 43 0.7× 51 0.9× 25 372
Elena Calama Spain 12 107 0.7× 63 0.7× 50 0.7× 134 2.1× 24 0.4× 23 323
Masahiko Ueno Japan 10 234 1.5× 49 0.5× 183 2.5× 42 0.7× 34 0.6× 11 583
Martin L. Reeves Canada 9 271 1.8× 31 0.3× 62 0.9× 127 2.0× 51 0.9× 13 358
Tsuneo Wakabayashi Japan 11 201 1.3× 30 0.3× 32 0.4× 69 1.1× 35 0.6× 40 480
Mary G. Huber United States 7 137 0.9× 124 1.3× 26 0.4× 125 2.0× 107 1.8× 9 393

Countries citing papers authored by Motonori Aoki

Since Specialization
Citations

This map shows the geographic impact of Motonori Aoki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Motonori Aoki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Motonori Aoki more than expected).

Fields of papers citing papers by Motonori Aoki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Motonori Aoki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Motonori Aoki. The network helps show where Motonori Aoki may publish in the future.

Co-authorship network of co-authors of Motonori Aoki

This figure shows the co-authorship network connecting the top 25 collaborators of Motonori Aoki. A scholar is included among the top collaborators of Motonori Aoki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Motonori Aoki. Motonori Aoki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Yatsu, Takeyuki, Motonori Aoki, & Akihiro Tanaka. (2005). Effect of zelandopam, a dopamine D1-like receptor agonist, in puromycin aminonucleoside nephrosis rats. European Journal of Pharmacology. 510(1-2). 121–126. 3 indexed citations
2.
Yatsu, Takeyuki, Motonori Aoki, Wataru Uchida, & Osamu Inagaki. (2005). Comparison between YM099 and Captopril in Rats with Renal Mass Reduction-Induced Progressive Renal Disease. Biological and Pharmaceutical Bulletin. 28(2). 367–369. 3 indexed citations
3.
Yatsu, Takeyuki, Motonori Aoki, & Osamu Inagaki. (2003). Preventive effect of zelandopam, a dopamine D1 receptor agonist, on cisplatin-induced acute renal failure in rats. European Journal of Pharmacology. 461(2-3). 191–195. 15 indexed citations
4.
Tsukada, Junko, Atsuo Tahara, Yuichi Tomura, et al.. (2002). Pharmacological characterization of YM471, a novel potent vasopressin V1A and V2 receptor antagonist. European Journal of Pharmacology. 446(1-3). 129–138. 13 indexed citations
5.
Wada, Koh‐ichi, Atsuo Tahara, Yukinori Arai, et al.. (2002). Effect of the vasopressin receptor antagonist conivaptan in rats with heart failure following myocardial infarction. European Journal of Pharmacology. 450(2). 169–177. 22 indexed citations
6.
7.
Aoki, Motonori, Shintaro Yamamoto, Miki Kobayashi, et al.. (2001). Antiasthmatic Effect of YM976, a Novel PDE4 Inhibitor, in Guinea Pigs. Journal of Pharmacology and Experimental Therapeutics. 297(1). 165–173. 25 indexed citations
8.
Aoki, Motonori, et al.. (2001). Studies on Mechanisms of Low Emetogenicity of YM976, a Novel Phosphodiesterase Type 4 Inhibitor. Journal of Pharmacology and Experimental Therapeutics. 298(3). 1142–1149. 36 indexed citations
9.
Aoki, Motonori, et al.. (2000). Effect of a Novel Anti-Inflammatory Compound, YM976, on Antigen-Induced Eosinophil Infiltration into the Lungs in Rats, Mice, and Ferrets. Journal of Pharmacology and Experimental Therapeutics. 295(3). 1149–1155. 29 indexed citations
10.
Aoki, Motonori, Miki Kobayashi, Jun Ishikawa, et al.. (2000). A Novel Phosphodiesterase Type 4 Inhibitor, YM976 (4-(3-Chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1H)-one), with Little Emetogenic Activity. Journal of Pharmacology and Experimental Therapeutics. 295(1). 255–260. 44 indexed citations
11.
Orita, Masaya, Satoshi Yamamoto, Naoko Katayama, et al.. (2000). Coumarin and Chromen-4-one Analogues as Tautomerase Inhibitors of Macrophage Migration Inhibitory Factor: Discovery and X-ray Crystallography. Journal of Medicinal Chemistry. 44(4). 540–547. 87 indexed citations
12.
Nagai, Hiroichi, Takanori Sengoku, Toru Miura, et al.. (1991). Anti-allergic action of gomisin A (TJN-101).. 40. 82. 1 indexed citations
13.
Yatsu, Takeyuki, Wataru Uchida, Kenji Takizawa, et al.. (1991). Renal effects of YM435, a novel dopamine DA1 receptor agonist, in anesthetized dogs.. The Japanese Journal of Pharmacology. 55. 344–344. 4 indexed citations
14.
Nagai, Hiroichi, et al.. (1989). Role of peptide-leukotrienes in liver injury in mice. Inflammation. 13(6). 673–680. 13 indexed citations
15.
Nagai, Hiroichi, et al.. (1989). Effect of OKY-046 and ONO-3708 on liver injury in mice.. The Japanese Journal of Pharmacology. 51(2). 191–197. 19 indexed citations
16.
Aoki, Motonori, et al.. (1989). The role of thromboxane A2 in experimental liver injury in mice.. Ensho. 9(3). 201–204. 3 indexed citations
17.
Nagai, Hiroichi, Motonori Aoki, Koji Teshima, et al.. (1989). The Effect of Gomisin A on Immunologic Liver Injury in Mice. Planta Medica. 55(1). 13–17. 8 indexed citations
18.
Nagai, Hiroichi, et al.. (1989). Effect of OKY-046 and ONO-3708 on Liver Injury in Mice. The Japanese Journal of Pharmacology. 51(2). 191–198. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kazuaki Naito Breakdown of academic impact, for papers by Hiromi Sugimoto Breakdown of academic impact, for papers by Katsuo Ikezawa Breakdown of academic impact, for papers by Richard G. Conway Breakdown of academic impact, for papers by Roberto P. Rosenkranz Breakdown of academic impact, for papers by Elena Calama Breakdown of academic impact, for papers by Masahiko Ueno Breakdown of academic impact, for papers by Martin L. Reeves Breakdown of academic impact, for papers by Tsuneo Wakabayashi Breakdown of academic impact, for papers by Mary G. Huber
Rankless by CCL
2026